)
Visual
test
Charles River Laboratories
Charles River Laboratories (CRL) investor relations material
Charles River Laboratories 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026
Business overview and market position
Operates as a non-clinical CRO with 20,000 employees and 120 global locations, holding leading market shares in Research Models, Safety Assessment, and Microbial segments.
70% of revenue comes from the pharmaceutical industry, with $4.05B in LTM 2025 revenue and strong free cash flow.
Three main segments: Research Models (~20-21%), Discovery and Safety Assessment (~60%), and Manufacturing Solutions (~19-20%).
Holds a 40% share in Research Models and 30% in Safety Assessment, with significant capabilities in bioanalysis and specialty testing.
65% of Manufacturing Solutions revenue is recurring, driven by strong IP and a razor/razor blade model.
Financial performance and strategic actions
LTM 2025 non-GAAP operating margin at 20.2% and non-GAAP EPS at $10.32, with free cash flow of $544M.
Operating margin and EPS have improved despite declining sales, with $295M in annualized cost savings targeted by 2026.
Announced divestiture of non-performing businesses representing 7% of revenue, expected to close by mid-year.
Two acquisitions: a Cambodian NHP supplier ($500M+) and PathoQuest ($60M), both expected to be accretive to margins and EPS, closing in 1Q26.
CapEx as a percentage of revenue reduced to 5.1%; $450M in stock buybacks last year and a new $1B authorization approved in October 2025.
Market trends and demand outlook
Pharma demand stabilized in early 2025; biotech demand improved in late 2025, supported by record capital inflows in Q4.
Book-to-bill ratio in DSA reached ~1.1 in Q4, driven by small and mid-size biotech clients.
Proposal and booking volumes are up, cancellations are down, but biotech decision timelines remain measured.
2026 organic revenue growth expected to be at least flat, with upside if book-to-bill remains above one and backlog moves quickly.
RMS and CDMO segments expected to benefit from improved biotech funding and loss of a large CDMO customer no longer a headwind.
How do acquisitions impact 2026 operating margin?
NAMs strategy impact on animal model demand?
DSA 2H26 revenue growth drivers?
NHP acquisition: supply security and margin uplift?
China DSA market entry strategy and competitive view
NAMs adoption timeline and impact on business segments
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebSCW
Q3 2025 revenue up 39% y/y, backlog at 58.3 mln PLN, and new strategy for optical payloads. - 6 FebSCW73% revenue growth and record backlog driven by new space contracts and strategic investments.
- 6 FebSCWRecord revenue, surging backlog, and major space contracts set the stage for 2025 growth.
- 6 FebSCWQ1 2025 revenue nearly doubled year-over-year, with strong backlog and major new contracts secured.
- 6 FebSCWRecord Q2 revenue, major new contracts, and a tripled backlog signal strong growth.
- 6 FebNVDA
AI-driven virtual twins and accelerated computing are revolutionizing design and manufacturing. - 6 FebSPKSJF
Record income, strong growth, and robust capital position despite lower interest income. - 6 FebISCTR
Net profit hit TL 67.4 billion in 2025, with strong NIM, fee growth, and solid 2026 outlook. - 6 FebCDP
2025 FFO/share rose 5.8% with strong leasing and retention; 2026 guidance signals further growth. - 6 FebPENG
All proposals passed, with no questions raised during the Q&A session.
Next Charles River Laboratories earnings date
Q4 202518 Feb, 2026
Charles River Laboratories
Next Charles River Laboratories earnings date
Q4 202518 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Charles River Laboratories International, Inc. is a concract research organization providing drug discovery, non-clinical development and safety testing services in the United States, Europe, Canada and the Asia Pacific regions. The Company provides research models and related services to support clients from target identification through non-clinical development. The Company operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage